AKAP6 and phospholamban colocalize and interact in HEK-293T cells and primary murine cardiomyocytes

Farigol Hakem Zadeh1,2, Allen C. T. Teng1,2, Uros Kuzmanov2, Paige J. Chambers3, Allan R. Tupling3 & Anthony O. Gramolini1,2

1 Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Ontario
2 Translational Biology and Engineering Program (TBEP), Ted Rogers Centre for Heart Research, Toronto, Ontario
3 Department of Kinesiology, University of Waterloo, Waterloo, Ontario

Keywords
A-kinase anchoring protein (AKAP), Ca2+ transport, heart, protein kinase A (PKA), sarcoplasmic reticulum (SR).

Correspondence
Anthony O. Gramolini, Department of Physiology, Faculty of Medicine, University of Toronto, Ted Rogers Centre for Heart Research, Translational Biology and Engineering Program, 661 University Avenue, Rm 1437, Toronto, ON, M5G 1M1 Canada. Tel: (416) 978-8257 E-mail: anthony.gramolini@utoronto.ca

Funding Information
This project was funded by the Heart and Stroke Foundation of Ontario (T-6281) to AOG; CIHR to AOG (MOP-106538); and the Heart and Stroke/Richard Lewar Centre of Excellence. FHZ held the Queen Elizabeth II Graduate Scholarship in Science and Technology. FHZ received an Ontario Graduate Scholarship. AOG was a Canada Research Chair in Proteomics and Molecular Therapeutics. ACTT received a Research Fellowship from the Heart and Stroke/Richard Lewar Centre of Excellence and Ted Rogers Centre for Heart Research.

Abstract
Phospholamban (PLN) is an important Ca2+ modulator at the sarcoplasmic reticulum (SR) of striated muscles. It physically interacts and inhibits sarcoplasmic reticulum Ca2+ ATPase (SERCA2) function, whereas a protein kinase A (PKA)-dependent phosphorylation at its serine 16 reverses the inhibition. The underlying mechanism of this post-translational modification, however, remains not fully understood. Using publicly available databases, we identified A-kinase anchoring protein 6 (AKAP6) as a candidate that might play some roles in PLN phosphorylation. Immunofluorescence showed colocalization between GFP-AKAP6 and PLN in transfected HEK-293T cells and cultured mouse neonatal cardiomyocytes (CMNCs). Co-immunoprecipitation confirmed the functional interaction between AKAP6 and PLN in HEK-293T and isolated adult rat cardiomyocytes in response to isoproterenol stimulation. Functionally, AKAP6 promoted Ca2+ uptake activity of SERCA1 in cotransfected HEK-293T cells despite the presence of PLN. These results were further confirmed in adult rat cardiomyocytes. Immunofluorescence showed colocalization of both proteins around the perinuclear region, while protein–protein interaction was corroborated by immunoprecipitation of the nucleus-enriched fraction of rat hearts. Our findings suggest AKAP6 as a novel interacting partner to PLN in HEK-293T and murine cardiomyocytes.
**Introduction**

In cardiomyocytes, SERCA2 is responsible for the majority of Ca^{2+} uptake from the cytosol into the SR (Li et al., 1998, Maclennan and Kranias 2003). SERCA2 activity is modulated via various biochemical modifications or protein interactions (Maclennan and Kranias 2003). PLN is a 52-amino acid transmembrane protein that interacts and inhibits SERCA2 function at the SR (Simmerman and Jones, 1998, Maslennikov et al., 1995). During end-stage heart failure, there is a decrease in SERCA2 activity due to a decrease in SERCA2 expression and an increased inhibitory effect of PLN on SERCA2 (Sankaranarayanan et al., 2016). Previous studies have identified three PLN mutations in heart failure patients with inherited cardiomyopathies. The first mutation is an Arg9 to Cys missense mutation (PLN-R9C), leading to an increased affinity toward PKA (Schmitt et al. 2003). The second mutation creates a de novo premature stop codon at Leu 39 (PLN-L39Stop). PLN-L39Stop is barely detectable in human cardiac tissues and is misrouted to the plasma membrane in transfected HEK-293 cells (Haghhi et al., 2003). The third PLN mutation has a deleted Arg14 residue (PLN-R14A), disrupting the di-arginine motif on positions 13 and 14 (R13/R14) of PLN that mediates retrograde transport of PLN protein with COPI vesicles from the Golgi apparatus back to the SR (Haghhi et al., 2006). Loss of R14 residue also disrupts the PKA recognition sequence (R-R-X-S/T) and PKA-mediated phosphorylation, rendering PLN-R14A highly inhibitory toward SERCA2 (Haghhi et al., 2006).

Ca^{2+}-cycling is critical to cardiac physiology, and PLN plays a key role in modulating Ca^{2+} uptake via an inhibitory interaction with SERCA2 (Zhao et al., 2009). Phosphorylation of PLN on either residue Ser16 by PKA or Thr17 by Ca^{2+}/calmodulin-dependent protein kinase II (CamKII) reverses PLN’s affinity toward SERCA2 (Tada and Katz 1982). During stress and sympathetic response in the heart, β-adrenergic receptor activation (Jones et al. 2012) increases Ca^{2+} uptake from the cytosol into the SR (Li et al., 1998, Maslennikov et al., 1995). During end-stage heart failure, there is a decrease in SERCA2 activity due to a decrease in SERCA2 expression and an increased inhibitory effect of PLN on SERCA2 (Sankaranarayanan et al., 2016). Previous studies have identified three PLN mutations in heart failure patients with inherited cardiomyopathies. The first mutation is an Arg9 to Cys missense mutation (PLN-R9C), leading to an increased affinity toward PKA (Schmitt et al. 2003). The second mutation creates a de novo premature stop codon at Leu 39 (PLN-L39Stop). PLN-L39Stop is barely detectable in human cardiac tissues and is misrouted to the plasma membrane in transfected HEK-293 cells (Haghhi et al., 2003). The third PLN mutation has a deleted Arg14 residue (PLN-R14A), disrupting the di-arginine motif on positions 13 and 14 (R13/R14) of PLN that mediates retrograde transport of PLN protein with COPI vesicles from the Golgi apparatus back to the SR (Haghhi et al., 2006). Loss of R14 residue also disrupts the PKA recognition sequence (R-R-X-S/T) and PKA-mediated phosphorylation, rendering PLN-R14A highly inhibitory toward SERCA2 (Haghhi et al., 2006).

Ca^{2+}-cycling is critical to cardiac physiology, and PLN plays a key role in modulating Ca^{2+} uptake via an inhibitory interaction with SERCA2 (Zhao et al., 2009). Phosphorylation of PLN on either residue Ser16 by PKA or Thr17 by Ca^{2+}/calmodulin-dependent protein kinase II (CamKII) reverses PLN’s affinity toward SERCA2 (Tada and Katz 1982). During stress and sympathetic response in the heart, β-adrenergic receptor activation (Jones et al. 2012) increases Ca^{2+} uptake from the cytosol into the SR (Li et al., 1998, Maslennikov et al., 1995). During end-stage heart failure, there is a decrease in SERCA2 activity due to a decrease in SERCA2 expression and an increased inhibitory effect of PLN on SERCA2 (Sankaranarayanan et al., 2016). Previous studies have identified three PLN mutations in heart failure patients with inherited cardiomyopathies. The first mutation is an Arg9 to Cys missense mutation (PLN-R9C), leading to an increased affinity toward PKA (Schmitt et al. 2003). The second mutation creates a de novo premature stop codon at Leu 39 (PLN-L39Stop). PLN-L39Stop is barely detectable in human cardiac tissues and is misrouted to the plasma membrane in transfected HEK-293 cells (Haghhi et al., 2003). The third PLN mutation has a deleted Arg14 residue (PLN-R14A), disrupting the di-arginine motif on positions 13 and 14 (R13/R14) of PLN that mediates retrograde transport of PLN protein with COPI vesicles from the Golgi apparatus back to the SR (Haghhi et al., 2006). Loss of R14 residue also disrupts the PKA recognition sequence (R-R-X-S/T) and PKA-mediated phosphorylation, rendering PLN-R14A highly inhibitory toward SERCA2 (Haghhi et al., 2006).
was used at a final concentration of 10 μmol/L in cell culture media, for 10 min (Bachmann et al., 2016). After 10 min, isoproterenol was removed and cells were lysed and prepared for immunoprecipitation. All animal experiments were approved by the University of Toronto Animal Care and Use Committee. We generated and assessed neonatal cardiomyocyte cultures from CD1 mouse neonates as published previously (Chis et al., 2012). The isolation of adult rat ventricular cardiomyocyte was performed as previously described (Lee et al., 2018).

**Lentiviral and adenoviral expression studies**

All plasmids used in this study were previously reported, including pLex-mCherry-Sec61/β, pEGFP-AKAP6, and pLex-NF-PLN (FLAG tag fused to the N terminal of PLN-WT, RA14, S16A, R9C, and L39Stop) (Kapiloff et al. 1999; Teng et al., 2015, Haghighi et al., 2006, Kimura et al. 1996). Lentiviral packaging was performed in HEK-293T cells as previously described, and virus was applied to isolated cardiomyocytes at 50 multiplicities of infection (MOI), which achieved >90% transduction efficiency (Teng et al., 2015). Adenoviral particles carrying short hairpin ribonucleic acid (shRNA) against rat AKAP6 or scrambled shRNA sequence were kindly provided by Hrishikesh Singh Thak and Michael Kapiloff (Pare et al. 2005a). Cardiomyocytes were transduced at 1000 MOI for 72 h.

**Immunoprecipitation and immunofluorescence**

For immunoprecipitation, 500 μg of rat cardiac lysate was incubated with 4 μg of antibody overnight at 4°C. The next day, the protein A/G agarose beads (Pierce) were blocked with 5% BSA in IP buffer (20 mmol/L HEPES; pH 7.4, 150 mmol/L NaCl, 1% Triton X-100, 5 mmol/L EDTA, 5% glycerol), supplemented with Roche complete protease inhibitor tablets (Roche, 11697498001) and phosphatase inhibitors for 1 h, and were added to the samples to be incubated for 2 h at 4°C. The samples were then washed and prepared for Western blotting.

Hearts from CD1 mice at 8–12 weeks of age were used for subcellular fractionation as described previously (Grasmolini et al. 2007). Briefly, 100 mg of cardiac tissues in 1 mL sucrose lysis buffer (250 mmol/L sucrose, 50 mmol/L Tris-HCl; pH7.4, 5 mmol/L MgCl₂) was homogenized at 10,000 rpm with a handheld homogenizer (Polytron, PT1200E) for 1 min, incubated on ice for 30 min, and spun at 800 g for 15 min. The pellet containing a nuclear enriched fraction was dissolved in nuclear extraction buffer. Non-nuclear impurity was removed by centrifuged at 80,000g for 35 min, and the nuclear fraction was resuspended in 50 mmol/L HEPES (pH 7.4), 10% glycerol, 1 mmol/L benzamidine, 1 mmol/L dithiothreitol (DTT), 5 mmol/L ethylenediaminetetraacetic acid (EDTA), 5 mmol/L ethylene glycol bis (β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 25 mmol/L sodium fluoride (NaF), 40 mmol/L sodium glycerophosphate, and 1 mmol/L sodium pyrophosphate (Kapiloff et al. 2001). For immunoblots, protein lysates were extracted from transfected HEK-293T cells in IP buffer, CMNCs in radioimmunoprecipitation assay (RIPA, 20 mmol/L Tris-HCl; pH7.4, 150 mmol/L NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate) buffer, and hearts also in RIPA buffer, supplemented with a protease inhibitor and phosphatase inhibitors. 30–100 μg of total proteins was fractionated by SDS-PAGE gels and transferred to 0.45 μm nitrocellulose membranes (Bio-Rad). Blots were incubated with the primary antibody overnight at 4°C and with the HRP-conjugated secondary antibody for 1 h at 22°C. Finally, the ECL Western blotting substrate (Pierce) was applied to membranes for 5 min before detected by ChemiDoc imaging systems (Bio-Rad). Primary antibodies and their dilution for immunoblotting are included below: Mouse monoclonal anti-FLAG antibody (Abcam, 1:1000), 1D11 mouse monoclonal antibody against PLN (kind gift from Dr. R. Johnson, 1:5000), mouse monoclonal anti-PLN antibody (Abcam, 1:1000), rabbit monoclonal A285 anti-phosphorylated PLN antibody (kindly provided by Dr. R. Johnson, 1:1000), rabbit polyclonal anti-AKAP6 antibody (EMD, Millipore Sigma, 1:1000), rabbit polyclonal anti-PKA IIz regulatory sc-908 antibody (Santa Cruz, 1:1000), mouse monoclonal anti-α-tubulin antibody (Hybridoma, 1:1000), and mouse monoclonal anti-lamin A/C sc-7292 antibody (Santa Cruz, 1:1000).

For immunofluorescence, isolated murine cardiomyocytes were fixed by 4% paraformaldehyde in PBS, permeabilized and blocked in blocking solution (1× PBS, 3% fetal bovine serum, 0.1% Triton X-100) for 10 min on ice. Samples were incubated overnight at 4°C with the primary antibodies diluted in blocking solution. Next morning, cells were washed and incubated with secondary antibodies and were imaged by ZEISS spinning disk confocal microscope. The primary antibodies and their dilution used for immunofluorescence include mouse monoclonal anti-FLAG antibody (Abcam, 1:500), 2D12 mouse monoclonal anti-PLN antibody (Abcam, 1:500), and mouse anti-mAKAP Antibody anti-mAKAP (OR017.720 – BioLegend, 1:500). The fluorophore-conjugated secondary antibodies (Alexa Fluor 488 & Alexa Fluor 633, 1:500 Life Technologies) were diluted in blocking solution.
**SERCA activity measurements**

ATPase activity of transfected HEK-293T cells was measured using a spectrophotometric plate reader (SPECTRAMAX plus; Molecular Devices) across Ca2+ concentrations ranging from pCa 7.0 to 4, as previously described by Duhamel et al. (2007). Details are available in the Supplemental information.

**Statistical analysis**

Using GraphPad Prism 5, one-way ANOVA analysis was utilized to test the differences and the significance among more than two groups with Tukey’s multiple-comparison test as post hoc. To compare two groups, unpaired t-test was performed. The data are expressed as mean ± SEM. A P-value <0.05 was considered significant.

More details on the experimental procedures are available on “Supporting information: Material and Methods” section of the Supporting Information [https://doi.org/10.6084/m9.figshare.7597517 or https://figshare.com/s/e2fc6084/m9.figshare.7597517] document.

**Results**

**RNA expression profile of all AKAPs in human heart tissues**

A previous study showed that AKAP7 could bridge between PKA and PLN in vitro (Rigatti et al. 2015), but targeted AKAP7 deletion in mouse hearts did not affect PLN phosphorylation following the adrenergic receptor activation (Jones et al. 2012), suggesting other cardiac AKAPs may be functionally compensating for the loss of AKAP7. As adaptor molecules, the levels of AKAP proteins mostly account for their functions. Thus, we first screened several transcriptomic, proteomic, and phosphoproteomic databases of human cardiac tissues at nondisease versus disease states. RNA levels of AKAPs were compared with publicly available RNA-sequencing (RNA-seq) data from the Human Protein Atlas (HPA), the Human Proteome Map (HPM), the gene-level dataset and Gene Expression Omnibus repository (GEO; Accession Number GSE89714), Genotype-Tissue Expression (GTEx), and the Functional Annotation of Mammalian Genome 5 (FANTOM5) (Fig. 1A) (Edgar et al. 2002; Takahashi et al. 2012, Consortium, G 2013; Kim et al. 2014; Uhlén et al. 2015). Although AKAP3 and AKAP4 are not expressed in the heart, in this study, they were used as negative controls with close to 0 detection level. Furthermore, PALM2-AKAP2 was not detected in GTEx data. In the HPM, HPA, GTEx, and GEO databases, the mean RNA expression levels of the AKAPs were normalized to the expression levels of SYNM which had the highest expression while in FANTOM5 database, the expression levels were normalized to AKAP2 levels (Fig. 1A). Transcripts of AKAP1, AKAP6, AKAP8L, and AKAP13 were consistently expressed at a higher level compared to remaining AKAPs in all datasets (Fig. 1A and B). Next, we sought to determine whether these transcript levels differ in the human disease model of hypertrophic cardiomyopathy, because impaired Ca2+ uptake is a common factor in failing hearts. Figure 1C showed that the transcripts of AKAP1, AKAP6, AKAP12, AKAP13, AKAP17A, and C2orf88 (chromosome 2 open-reading frame 88) were different between nondisease versus disease conditions. To visualize AKAPs with fold changes versus statistical significance (P < 0.05), a volcano plot was used (Kuzmanov et al. 2018). Figure 1D shows 7 AKAPs had a significant alteration in transcript levels between human nonhypertrophic and hypertrophic samples, including AKAP1, AKAP6, AKAP10, AKAP12, AKAP13, AKAP17A, and C2orf88.

**Protein expression profile of human AKAPs and protein localization**

In order to identify AKAPs that have alterations in their phosphorylation and functionality during disease states, we investigated previous phosphoproteomic data collected from human HCM patients (Data available via ProteomeXchange; identifier PXD011107). Phosphosite levels were analyzed using quantile, width adjustment in Perseus software (Tyanova et al. 2016). The first, second, and third quartiles (q1, q2, q3) were calculated from the distribution of all values. The second quartile (the median) was subtracted from each value to center the distribution. Values were then divided by the width in an asymmetric way. All values that were positive following subtraction of the median were divided by q3-q2, while all negative values were divided by q2-q1. Differences in the detected phosphorylation sites among AKAPs were plotted (Fig. 2A). We identified phosphorylation sites for four major AKAPs and that AKAP2 (S720), AKAP6 (S424, S481 and S455), AKAP12 (S1331 and S1395), and AKAP13 (S2720) were different between nondisease versus disease states. To visualize AKAPs with fold changes versus statistical significance (P < 0.05), a volcano plot was used (Kuzmanov et al. 2018). Figure 1D shows 7 AKAPs had a significant alteration in transcript levels between human nonhypertrophic and hypertrophic samples, including AKAP1, AKAP6, AKAP10, AKAP12, AKAP13, AKAP17A, and C2orf88.

We next examined subcellular localization of AKAP1, AKAP6, AKAP7, AKAP12, AKAP13, and SYNM in the human heart available in the Human Protein Atlas (Uhlén et al. 2015). Figure 2C shows that AKAP6 was positive on the SR and the nuclear membrane (NE), while AKAP13
staining was predominantly cytosolic. By contrast, AKAP1, AKAP12, and SYNM had minimal to no sarcomeric or SR staining pattern, with no apparent nuclear envelope staining (Fig. 2C). As controls, staining was also compared to abundant cardiac markers, including SERCA2, PLN, myosin heavy chain 6 (MYH6), connexin 43 (Cx43), and lamin B1 (LMNB1) (Fig. 2D). Together, based on these results, it is suggested that AKAP6 is a potential candidate for facilitating PLN phosphorylation in the heart.

**AKAP6 localization in HEK-293T cells**

Next, we sought to determine whether AKAP6 would localize to the endoplasmic reticulum (ER)/SR region, starting in HEK-293T cells. Immunofluorescence shows that GFP-tagged AKAP6 (GFP-AKAP6) colocalized with an endoplasmic reticulum marker mCherry-Sec61 (Fig. 3), whereas mCherry control did not. Specifically, three-dimensional reconstructions of these cells using Imaris showed 83 ± 1% of GFP-AKAP6 signals colocalized with 91 ± 1% mCherry-Sec61, with a Pearson’s coefficient of 0.91 ± 0.01 (25 cells were quantified) (Fig. 3), while, in the negative control condition, 18 ± 3% of GFP-AKAP6 was colocalized with 27 ± 1% of mCherry (Pearson’s coefficient = 0.3 ± 0.05). GFP-AKAP6 was also found in the perinuclear region of transfected HEK-293T cells. Together, these results corroborated the findings of AKAP6 localized to the SR and the nuclear envelope (NE) in HEK-293T cells.

**AKAP6 and PLN colocalize and co-immunoprecipitate in HEK-293T cells**

We next explored whether AKAP6 and PLN would colocalize in transfected HEK-293T cells. ImmunobLOTS first
confirmed successful expression and detection of GFP-AKAP6 and FLAG-tagged PLN (NF-PLN) in transfected cells (Fig. 4A). Immunofluorescence and three-dimensional reconstructions of 30 independently transfected cells showed 58% GFP-AKAP6 colocalized with 77% NF-PLN with a mean Pearson’s coefficient of 0.69 ± 0.02 (Fig. 4B). GFP-AKAP6 and endogenous PLN also colocalized in 30 independently examined CMNCs (Fig. 4C). To determine whether GFP-AKAP6 and PLN biochemically interact, co-immunoprecipitation (Co-IP) of NF-PLN and GFP-AKAP6 was performed with transfected HEK-293T lysates. Figure 4D shows NF-PLN immunoprecipitation led to GFP-AKAP6 co-precipitation. We were unable to immunoprecipitate AKAP6 with either the Biolegend or Millipore antibody, and thus, reverse Co-IPs were not possible. Together, our results show AKAP6 and PLN could colocalize and biochemically interact in HEK-293T cells.
SERCA activity profile upon AKAP6 and PLN overexpression in HEK-293T

We next sought to determine the functional importance of PLN and AKAP6 interaction with Ca^{2+} ATPase assays that would compare the effect of AKAP6-PLN-SERCA1, PLN-SERCA1, and SERCA1 only in transfected HEK-293T cells. In this experiment, the Ca^{2+} affinity (K_a) of SERCA1 slightly (albeit insignificantly) dropped when PLN (WT) was cotransfected (from 6.0 ± 0.1 pCa units in SERCA1 only to 5.8 ± 0.2 pCa units in SERCA1 + PLN, P = 0.05). Interestingly, upon the overexpression of AKAP6, the K_a significantly shifted to 6.2 ± 0.4 pCa units compared to the SERCA1 + PLN group (Fig. 5A, *P = 0.03). All assays showed similar V_{max} (SERCA1, 16.7 ± 2.3 μmol/min/mg, SERCA1 + PLN, 17.1 ± 3.6 μmol/min/mg; Fig. 5B, n = 5, P > 0.1). Our results show that the presence of AKAP6 could reverse the inhibitory effect of PLN on SERCA1 in HEK-293T cells.

AKAP6 and PLN interactions

To explore any physical interaction between AKAP6 and PLN mutants (S16A, R9C, RA14, or L39Stop), Co-IP experiments were performed in transfected HEK-293T cells, because no commercially available AKAP6 antibody could be used for immunoprecipitation. Figure 6 shows that all NF-LN constructs were immunoprecipitated with FLAG antibody, but the level of NF-PLN (S16A) precipitated was much less than NF-PLN (WT) conditions (19 ± 5% in untreated NF-PLN (S16A) compared to 100% in untreated NF-PLN (WT); 24 ± 5% for isoproterenol-treated NF-PLN (S16A) compared to 99 ± 3% for isoproterenol-treated NF-PLN (WT)). Consistent with Figure 4D, NF-PLN (WT) and GFP-AKAP6 formed a biochemical interaction in HEK-293T cells. Isoproterenol treatment, which promoted PLN phosphorylation at the Ser16 residue, however, reduced PLN-AKAP6 interaction (56 ± 20% in isoproterenol-treated versus 100% in untreated samples, P < 0.05, Fig. 6). Interestingly, three disease-causing PLN mutants (R9C, RA14, and L39Stop) had increased biochemical interactions with AKAP6 in response to isoproterenol stimulation. Finally, the NF-PLN (S16A) had the strongest interaction (208 ± 17%) with AKAP6 of all tested PLN variants. In addition, isoproterenol treatments did not change this interaction (Fig. 6). Phosphorylation status of PLN proteins was also assessed by immunoblots. Upon isoproterenol stimulation, three PLN (WT, R9C, and L39Stop) had increased phosphorylation signals, while the phosphorylation status on two other PLN (RA14 and S16A) was not detectable (Fig. 6). Lastly and as expected, in all cases, the PKA was detected in the co-precipitated protein complexes, because PKA was possibly anchored to the precipitated AKAP6. Nevertheless, NF-PLN (RA14) showed higher, albeit not statistically significant, levels of PKA interaction (normalized density of 154 ± 20% untreated and 132 ± 8% isoproterenol-treated) compared to the WT NF-PLN 100% untreated and 82 ± 13% isoproterenol-treated (Fig. 6). Together, our results show that PLN and variants biochemically interacted with AKAP6 differentially in HEK-293T cells.
Figure 4. AKAP6 interaction with NF-PLN-WT in HEK-293T cells. (A) Immunoblots confirmed overexpression of NF-PLN and GFP-AKAP6 in transfected HEK-293T cells. Same blots split and processed with the same intensity scaling. Top blotted with anti-FLAG antibody to detect NF-PLN: First lane: control empty pLex transfection after 5 min boiling. Second lane: NF-PLN and GFP-AKAP6 transfection with 5 min boiling. Third lane: NF-PLN and GFP-AKAP6 transfection after no boiling. Bottom blotted with anti-GFP antibody to detect GFP-AKAP6: for GFP-AKAP6. First lane: control empty pLex transfection after 5 min boiling. Second lane: NF-PLN and GFP-AKAP6 transfection with 5 min boiling. (B) Confocal imaging and 3D reconstruction showing colocalization of GFP-AKAP6 and NF-PLN (WT) in HEK-293T cells (n = 3 independent transfection experiments, at least 10 cells were included per calculation, N = 30 total cells). Scale bar, 10 μm. (C) Immunofluorescence showing colocalization between PLN and GFP-AKAP6 signals in neonatal mouse cardiomyocyte cultures (n = 3 independent transfection experiments, at least 6 cells were included per calculation, N = 20 total cells). Immunofluorescence was performed with the following: (1) 1D11 (anti-PLN) antibody for PLN detection, (2) anti-GFP antibody for GFP-AKAP6 detection. Scale bar, 10 μm. (D) Immunoprecipitation showing NF-PLN (WT) and GFP-AKAP6 physically interacted in transfected HEK-293T cells. All samples were boiled prior to electrophoresis. (1) NF-PLN pull-down with anti-FLAG antibody and detection of NF-PLN through immunoblotting with anti-FLAG antibody. The bands observed at 25 kDa and 50 kDa are IgG the light chain and heavy chain. (2) NF-PLN Lysate input signal detection through immunoblotting with anti-FLAG antibody. (3) NF-PLN pull-down with anti-FLAG antibody and detection of GFP-AKAP6 through immunoblotting with anti-GFP antibody. The bands observed close to 100 kDa are IgG aggregates formed by boiling prior to electrophoresis. (4) GFP-AKAP6 Lysate input signal detection through immunoblotting with anti-GFP antibody. Full immunoblots of all the blots were included in Figure S1 within the Supporting Information [DOI: 0.6084/m9.figshare.7597517 or https://figshare.com/s/e2f3685b0c62d59378b7] document.
Colocalization and biochemical interaction between PLN and AKAP6 in rat adult ventricular cardiomyocytes

To investigate the colocalization of endogenous AKAP6 and PLN in the heart, we performed immunofluorescence in isolated rat adult ventricular cardiomyocytes (AVC). Figure 7A shows that endogenous AKAP6 and PLN independently localized to the SR and NE regions (Fig. 7A, top panels). Colocalization study was not possible because both AKAP6 and PLN antibodies were raised from mice. To determine the specific localization of endogenous AKAP6 in the heart, we performed a differential centrifugation, organellar fractionation of the whole heart to isolate a nuclear-, microsomal/SR-, and mitochondrial-enriched fractions (Gramolini et al. 2007). Immunoblots for AKAP6 in these fractions showed that AKAP6 was highly expressed in the nuclear fraction, with no detection of the high molecular mass product in the other two fractions. A smaller product (220 kDa), however, was detected in the SR/microsomal fraction, which may represent a slicing AKAP6 variant (Fig. 7B) (Wu et al. 2010).

Since the biochemistry showed that the majority of the AKAP6 signal was in a nuclei-enriched fraction, not the microsomal fraction that would contain the majority of the ER/SR, and the prevailing expression pattern was outside of the nucleus, we sought to carefully examine the specificity of the AKAP6 antibody by fluorescent microscopy. Adult cardiomyocytes were transduced with adenovirus carrying AKAP6 shRNA (Ad-U6 AKAP6 721D mp2A) or a scrambled shRNA (AKAP6 721D mut.C), followed by immunofluorescence. We did not observe any differences in cells treated with the scrambled sequence (Fig. 7C). However, the AKAP6 knockdown cells lost the nuclear staining, while the striated SR staining pattern persisted. Quantification of these experiments in 45 AKAP6 shRNA cells showed that >70% of them had no remaining nuclear staining, despite considerable fluorescence remaining at the sarcomere. More than 90% of the control cells (transfected with AKAP6 scrambled) showed prominent nuclear staining (Table 1). Together, these results show that most of the SR staining in the cardiomyocytes was due to nonspecific binding of the antibody, whereas the perinuclear staining was antibody-specific. Focusing only on this specific perinuclear staining of AKAP6 and PLN, following 3D reconstruction of stained cardiomyocytes, both AKAP6 and PLN had distinct perinuclear staining (Fig. 7D).

To determine the binding interaction between endogenous AKAP6 and PLN in the perinuclear and nuclear region of adult hearts, we performed Co-IP of the endogenous PLN and AKAP6 with enriched nuclear fractions isolated from adult rat hearts. As demonstrated in Figure 7E, PLN precipitation in this fraction resulted in AKAP6 co-precipitation compared to control samples showing no PLN and AKAP6 binding to nonspecific IgG. These data suggest that endogenous AKAP6 and PLN interact in the perinuclear region of adult rat cardiomyocytes.

Discussion

One downstream effect of β-adrenergic stimulation in the heart is the activation of the cAMP/PKA signaling pathway (Xiang and Kobilka 2003). Upon activation, PKA initiates the phosphorylation of several Ca2+-cycling-related proteins such as PLN and RyR2 (Reddy 1976; Tada and Katz 1982; Koss and Kranias 1996). AKAPs are important scaffold proteins that target PKA to its effectors in an organelle-specific manner. The structural role of these AKAPs is not exclusive to PKA phosphorylation pathways, and they mediate the activity of several other enzymes at different subcellular regions (Nauert et al. 1997; Eide et al. 1998; Fraser et al. 1998; Mizuno et al. 2001). Thus, a comprehensive study of AKAP protein and...
their phosphorylation status in given cells or organs is important for mapping AKAP-dependent signaling pathways, similar to conventional kinase-mediated singling network. Here, we took the liberty of establishing the first AKAP transcriptome and phosphoproteome of human hypertrophic hearts (Figs. 1 and 2). To our best knowledge, this is the first systematic approach in profiling human cardiac AKAPs, although Scholten et al. 2007 reported the first mouse ventricular AKAP profiling. Human patient samples were limited to only hypertrophic cardiomyopathy due to limited availability of robust datasets, but the expansion of a similar analysis would likely extend the implications of our work. Another limitation includes human nonhypertrophic tissues, which were naturally difficult to obtain. Our study revealed that AKAP1, AKAP6, AKAP10, AKAP12, AKAP13, AKAP17A, and C2orf88 are differentially expressed following cardiac hypertrophy (Fig. 1D), while AKAP2, AKAP6, AKAP12, and AKAP13 had significantly altered phosphorylation status (Fig. 2A). Our findings were further validated by existing reports. For example, Li et al. (2017b) showed that targeted deletion of AKAP12 improved cardiac contraction, which was attributed to alteration in RYR2 phosphorylation. Evidently, Pare et al. (2005a) showed that AKAP6 mediated cardiac hypertrophy in rat hearts also via RYR2 phosphorylation. Collectively, these reports and our study illustrate the complexity and duplicated functions of AKAPs and thus the importance of profiling AKAP expression, post-translational modifications, and protein–protein interactions in biological sources. Although proteogenomic (proteomic + genomic) approaches are often used for hypothesis generating, these tools are not without weaknesses. One potential limitation includes quantitative bias. For instance, signals of low expression proteins can be lost in a noisy background in proteomic searches. The signal-to-noise ratio can be further improved in prospective proteogenomic research with the advent of new technologies and computer algorithms.

PLN functions as an inhibitor to SERCA in striated muscle, but its inhibitory effect is reversed by PKA-mediated phosphorylation on the Ser16 residue (Maclellan and Krnias 2003). Loss of PKA recognition site, as
Figure 7. AKAP6 and PLN localization and immunoprecipitation in AVC. (A) (1) methanol fixation or (2) paraformaldehyde fixation followed by AKAP6, PLN, and phalloidin staining. No adenoviral transduction. Harvested 1 day after plating. Scale bar, 20 μm. (B) AKAP6 subcellular localization in adult rat cardiomyocytes. (C) Immunofluorescence showing AKAP6 localization to the perinuclear region in adult rat cardiomyocytes. Adenovirus carrying scrambled (scram) or AKAP6 shRNA was used to silence endogenous AKAP6. AKAP6 shRNA resulted in the loss of protein signal around the perinuclear region. Harvested 3 days post-transduction. Scale bar, 20 μm. (D) 3D reconstruction of PLN and AKAP6 at the perinuclear, nuclear, and nuclear invagination in AVC (n = 45–50 cells per condition). No adenoviral transduction. Harvested 3 day post-transduction. (E) Endogenous AKAP6 and PLN immunoprecipitation assays in adult rat hearts. IP was performed using 1D11 (anti-PLN) antibody to immunoprecipitate endogenous PLN. Samples were immunoblotted with: 1D11 (anti-PLN) antibody for PLN band detection, anti-AKAP6 antibody for endogenous AKAP6 detection, PLN input, AKAP6 input, and a-tubulin control input (n = 3). Full immunoblots of all the blots were included within the Supporting information [https://doi.org/10.6084/m9.figshare.7597517 or https://figshare.com/s/e2f13685b0c62d59378b7] document. Quantification of the number of WT (no transduction, n = 86 nuclei), Control (Scram) (n = 76 nuclei) and AKAP6 KD (n = 76 nuclei) cells containing or lacking AKAP6 staining are included in Table 1.
exemplified by the PLN-RA14 mutant, renders it super inhibitory and is associated with arrhythmogenic right ventricular cardiomyopathy in human patients (van der Zwaag et al. 2012; Te Rijdt et al. 2019). It is currently under debate which AKAPs mediate PKA-PLN interactions in cardiomyocytes. Previous studies identified AKAP 7/18β as the mediator of PLN phosphorylation through PKA (Lygren et al. 2007). Experiments using the KO model of AKAP 7/18β, nevertheless, did not show a significant disruption in cardiac function following adrenergic stimulation (Jones et al. 2012). Furthermore, a recent study illustrated a significant interaction between PLN and AKAP6. Yet, a conditional KO of AKAP5 in mice only partial perturbed adrenergic responses of the heart (Li et al. 2017a). Similarly, another recent study in mouse SYN M knockouts showed a very minor decrease in PKA-RII phosphorylation with no concomitant changes in Ca^{2+}-transient kinetics (García-Pelagio et al. 2018). In this study, we identified AKAP6 as a candidate that mediates PLN phosphorylation. Figures 5 and 7G show that PLN and AKAP6 biochemically interacted in transfected HEK-293T cells and rat hearts. Immunofluorescence showed that PLN and AKAP6 independently colocalize at the perinuclear region of rat ventricular myocytes (Fig. 7F). Functionally, AKAP6 expression removed the inhibitory effect of PLN on SERCA1 (Fig. 6B). Together, this study suggests AKAP6 as a modulator for PLN phosphorylation at the perinuclear region of cardiomyocytes and, together with other AKAPs, co-regulate PLN phosphorylation and function.

Our immunofluorescence studies showed that AKAP6 was localized to the ER/SR in transfected HEK-293T cells and CMNCs, but was restricted to the perinuclear region in adult cardiomyocytes. Two hypotheses may account for this difference. First, there are considerable numbers of AKAP6 transcriptional or splicing variations. Some of those variants show SR staining patterns (Yang et al. 1998; Schulze et al. 2003; Faul et al. 2007), and others are restricted to the perinuclear region of myocytes (Kapiloff et al. 1999, 2001; Pare et al. 2005b; Kritzer et al. 2014).

Our data using shRNA studies to highlight AKAP6 antibody-specific staining, along with our organellar fractionation data, support preferential expression at the perinuclear domain in myocytes (Passariello et al. 2015). However, our finding could not rule out the possibility of the SR-localized AKAP6 in adult rat cardiomyocytes, since autofluorescence from cardiac sarcomeric structure tends to overshadow the genuine, but weaker, immunofluorescent signals (Larcher et al. 2018). Secondly, a skewed ratio of endogenous Nuclear envelope spectrin-repeat proteins 1 (Nesprin-1) to the overexpressed AKAP6 may account for this discrepancy. Nesprin family proteins are intermediate filament proteins located on the outer nuclear membrane of cells. Currently, four Nesprin family members are identified, and they are responsible for connecting the nuclei to different types of cytoskeletons. While they all physically connect to the C-terminal end of trimeric Sad1p-UNC84 (SUN) complexes at the inner nuclear membrane, Nesprin 1/2 interact with F-actin, Nesprin 3 with Plectin, and Nesprin 4 with microtubules in the cytoplasm (Rajgor and Shanahan 2013). A previous study showed that AKAP6 anchoring to the outer nuclear membrane depended on Nesprin 1 in African green monkey kidney COS7 cells (Pare et al. 2005b). In HEK-293T cells, overexpressed AKAP6 may not be anchored to the outer nuclear membrane due partially to limited numbers of endogenous Nesprin 1 (Fig. 3). This observation reaffirms our finding that PLN and AKAP6 could interact at the Nesprin 1-positive outer nuclear membrane of adult rat cardiomyocytes (Fig. 7F).

Our data showed an interaction between endogenous AKAP6 and PLN in the nuclear fraction of the adult rat hearts. Interestingly, AKAP6 is known to regulate PKA proteins activated through β2-adrenergic receptors (AR) rather than β1-AR at the level of the nucleus (Bedioune et al. 2018). It is known that unlike β1-AR, β2-AR is less involved in eliciting excitation–contraction events in cardiomyocytes (Xiao and Lakatta 1993). However, the high localization and interaction of PLN with AKAP6 at the perinuclear region suggests that, similar to RYR2 and β2-

### Table 1. Quantification of the number of AVCs with nuclear stain upon transduction with adenovirus carrying scrambled or AKAP6 shRNA.

| Conditions | WT | Control | AKAP6-KD |
|------------|----|---------|----------|
| **A**      |    |         |          |
| Total cells|    |         |          |
| # Cells (% cells) | 50 | 44      | 45       |
| With nuclear stain | 44 (88%) | 40 (91%) | 12 (26.7%) |
| **B**      |    |         |          |
| Total nuclei | 86 | 76      | 80       |
| # Nuclei (% nuclei) | 77 (89.5%) | 69 (90.8%) | 20 (25%)  |
| With nuclear stain |        |         |          |
AR activated PKA, PLN activity is regulated by AKAP6 at the level of the nucleus (Kapiloff et al. 2001). Interestingly, Zhou et al. 2015 showed that palmitoylated PLN was identified at the perinuclear region of adult mouse cardiomyocytes, while perinuclear PLN was suggested to play a role in modulating Ca\(^{2+}\) uptake and gene expression in adult mouse cardiomyocytes (Ljubojevic and Bers 2015; Wu et al. 2016; Chen et al. 2018). One future approach to elucidate the specific AKAP6 and PLN downstream effects can be investigated through knocking out AKAP6 and recording Ca\(^{2+}\)-cycling changes particularly at the nuclear envelope.

The Ca\(^{2+}\) uptake assays of transfected HEK-293T cells with overexpressed SERCA1, SERCA1 + NF-PLN, SERCA1 + NF-PLN+GFP-AKAP6 showed that while PLN expression inhibited SERCA1 activity by lowering the K\(_a\) of SERCA1, AKAP6 reversed PLN inhibition. These data suggest AKAP6 is capable of mediating PLN activation–inactivation processes, at least in HEK-293T cells. One small caveat of using NF-PLN is the unknown biochemical impact of negatively charged FLAG peptide to the full-length PLN. Kimura et al. (1996) showed that FLAG tag, when directly fused to the membrane domain (PLN28-52) of PLN, rendered it more inhibitory towards SERCA2. Similarly, Kleinschmidt et al. (1997) showed that negatively charged lipid had an inhibitory effect toward SERCA2. Conversely, phosphorylation of Ser16 or Thr17 on PLN reverses its binding toward SERCA2, despite the negative charges from phosphorylated residues. Future studies in how FLAG tag may impact PLN/AKAP6 interactions should be explored.

Our investigation of AKAP6 and PLN mutants (R9C, L39Stop, R14, and S16A) provides some insights; for example, we detected a higher level of PLN-R9C phosphorylation upon isoproterenol activation which is consistent with the earlier proposed PKA “trapping” by the PLN-R9C structure (Schmitt et al. 2003). Furthermore, PLN-L39Stop showed a significantly higher level of phosphorylation upon isoproterenol treatment. This result might be due to misrouted localization of PLN-L39Stop to other subcellular regions and its interaction with different kinase populations in the cytosol as well as membranous compartments. Similarly, we detected a higher level of AKAP6 pull-down with PLN (S16A) compared to PLN (WT) both with and without adrenergic stimulation. Based on our phospho-PLN immunoblots and in accordance with previous literature, it is known that PLN (S16A) cannot be phosphorylated, and therefore, it is possible that a more stable AKAP6-S16A complex forms within the precipitated protein. Finally, our study showed lack of PLN phosphorylation in PLN-RA14. This observation might be due to the distortion in PKA recognition site (R-R-X-S) because of the lack of Arg14 in PLN structure (Masterson et al. 2010).

In conclusion, our study showed high colocalization and biochemical interaction between AKAP6 and PLN in HEK-293T. This finding was further corroborated in rat cardiac tissues and isolated adult cardiomyocytes. In adult cardiomyocytes, the regulation of protein phosphorylation events by different PKA pool is highly compartmentalized. Although several unknown questions about the Ca\(^{2+}\) signaling events at the nuclear level still remain unanswered, our findings showed that the regulation of Ca\(^{2+}\) signaling proteins such as PLN is highly specialized and was dependent upon their spatial localization and the regulators that exist in their proximity. Consistently, Chen et al. (2018) showed that perinuclear PLN of mouse ventricular myocytes modulated nuclear Ca\(^{2+}\) handling by controlling RyR2 and IP3R activities. Given that the specificity of AKAP6 is due to its precise localization to the nuclear region in mature myocytes, our findings support a critical role of AKAP6 in regulating phosphorylation of several important nuclear Ca\(^{2+}\)-cycling proteins, with clear potential to affect critical transcriptional events downstream. Future studies examining and clarifying its impact are required to delineate its role more fully.

Acknowledgment

We thank Wenping Li for expert technical assistance. We thank Michael Kapiloff, Hrishikesh Singh Thak, and Jinliang Li for the adenovirus shRNA AKAP6 and helpful discussions on this manuscript.

Conflict of Interest

The authors declare that they have no conflict of interests with the contents of this article.

References

Bachmann, V. A., J. E. Mayrhofer, R. Illouz, P. Tschakner, P. Rafféiner, R. Röck, et al. 2016. Gpr161 anchoring of PKA consolidates GPCR and cAMP signaling. Proc. Natl. Acad. Sci. USA 113:7786–7791.
Bedioune, I., F. Lefebvre, P. Lechène, A. Varin, V. Domergue, M. S. Kapiloff, et al. 2018. PDE4 and mAKAPβ are nodal organizers of β2-ARs nuclear PKA signaling in cardiac myocytes. Cardiovasc. Res. 114:1499–1511.
Chen, M., D. Xu, A. Z. Wu, E. Krnias, S. F. Lin, P. S. Chen, et al. 2018. Phospholamban regulates nuclear Ca. J. Mol. Cell. Cardiol. 123:185–197.
Chis, R., P. Sharma, N. Bousette, T. Miyake, A. Wilson, P. H. Backx, et al. 2012. α-Crystallin B prevents apoptosis after H2O2 exposure in mouse neonatal cardiomyocytes. Am. J. Physiol. Heart. Circ. Physiol. 303:H967–H978.
Consortium, G. 2013. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45:580–585.

Diviani, D., K. L. Dodge-Kafka, J. Li, and M. S. Kapiloff. 2011. A-kinase anchoring proteins: scaffolding proteins in the heart. Am. J. Physiol. Heart Circ. Physiol. 301:H1742–H1753.

Diviani, D., D. Maric, I. Pérez López, S. Cavin, and C. D. Del Vescovo. 2013. A-kinase anchoring proteins: molecular regulators of the cardiac stress response. Biochim. Biophys. Acta 1833:901–908.

Duhamel, T. A., H. J. Green, R. D. Stewart, K. P. Foley, I. C. Diviani, D., R. D. Stewart, K. P. Foley, I. C. Diviani, D., K. L. Dodge-Kafka, J. Li, and M. S. Kapiloff. 2011. Consortium, G. 2013. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45:580–585.

Duhamel, T. A., H. J. Green, R. D. Stewart, K. P. Foley, I. C. Smith, and J. Ouyang. 2007. Muscle metabolic, SR Ca(2+) - cycling responses to prolonged cycling, with and without glucose supplementation. J. Appl. Physiol. 103:1986–1996.

Edgar, R., M. Domrachev, and A. E. Lash. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207–210.

Eide, T., V. Coghlan, S. Orstavik, C. Holse, R. Solberg, B. S. Skalhegg, et al. 1998. Molecular cloning, chromosomal localization, and cell cycle-dependent subcellular distribution of the A-kinase anchoring protein, AKAP95. Exp. Cell Res. 238:305–316.

Faul, C., A. Dhume, A. D. Schecter, and P. Mundel. 2007. Protein kinase A, Ca2+ /calmodulin-dependent kinase II, and calcineurin regulate the intracellular trafficking of myopodin between the Z-disc and the nucleus of cardiac myocytes. Mol. Cell. Biol. 27:8215–8227.

Fraser, I. D., S. J. Tavalin, L. B. Lester, L. K. Langeberg, A. M. Westphal, R. A. Dean, et al. 1998. A novel lipid-anchored A-kinase Anchoring Protein facilitates cAMP-responsive membrane events. EMBO J. 17:2261–2272.

García-Pelagio, K. P., L. Chen, H. C. Joca, C. Ward, W. Jonathan Lederer, and R. J. Bloch. 2018. Absence of synemin in mice causes structural and functional abnormalities in heart. J. Mol. Cell. Cardiol. 114:354–363.

Gramolini, A. O., T. Kislinger, P. Liu, D. H. Maclennan, and A. Emili. 2007. Analyzing the cardiac muscle proteome by liquid chromatography-mass spectrometry-based expression proteomics. Methods Mol. Biol. 357:15–31.

Haghighi, K., F. Kolokathis, A. O. Gramolini, J. R. Waggoner, L. Pater, R. A. Lynch, et al. 2006. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl. Acad. Sci. USA 103:1388–1393.

Haghighi, K., F. Kolokathis, L. Pater, Lynch, R. A., Asahi, M., Gramolini, A. O., et al. 2003. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111:869–876.

Jones, B. W., S. Brunet, M. L. Gilbert, C. B. Nichols, T. Su, R. E. Westenbroek, et al. 2012. Cardiomyocytes from AKAP7 knockout mice respond normally to adrenergic stimulation. Proc. Natl Acad. Sci. USA 109:17099–17104.

Kapiloff, M. S., R. V. Schillace, A. M. Westphal, and J. D. Scott. 1999. mAKAP: an A-kinase anchoring protein targeted to the nuclear membrane of differentiated myocytes. J. Cell Sci. 112(Pt 16):2725–2736.

Kapiloff, M. S., N. Jackson, and N. Airthart. 2001. mAKAP and the ryanodine receptor are part of a multi-component signaling complex on the cardiomyocyte nuclear envelope. J. Cell Sci. 114:3167–3176.

Kim, M. S., S. M. Pinto, D. Getnet, R. S. Nirujoji, S. S. Manda, R. Chaerkady, et al. 2014. A draft map of the human proteome. Nature 509:575–581.

Kimura, Y., K. Kurzydlowski, M. Tada, and D. H. Maclennan. 1996. Phospholamban regulates the Ca2+ + ATPase through intramembrane interactions. J. Biol. Chem. 271:21726–21731.

Kleinschmidt, J. H., J. E. Mahaney, D. D. Thomas, and D. Marsh. 1997. Interaction of bee venom melittin with zwitterionic and negatively charged phospholipid bilayers: a spin-label electron spin resonance study. Biophys. J. 72:767–778.

Koss, K. L., and E. G. Kranias. 1996. Phospholamban: a prominent regulator of myocardial contractility. Circ. Res. 79:1059–1063.

Kritzer, M. D., J. Li, C. L. Passariello, M. Gayanilo, H. Thakur, J. Dayan, et al. 2014. The scaffold protein muscle A-kinase anchoring protein β orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure. Circ. Heart Fail. 7:663–672.

Kuzmanov, U., H. Guo, S. Hadipour-Lakmehsari, P. Sharma, P. Billia, A. Emili, et al. 2018. Global human and mouse phosphoproteomic profiling of signaling pathway aberrations in hypertrophic cardiomyopathy. HUPO 2018 World Congress, 2018 Orlando, FL. HUPO, Log number 87.

Larcher, V., P. Kunderfranco, M. Vacciano, P. Carullo, M. Erreni, I. Salamon, et al. 2018. An autofluorescence-based method for the isolation of highly purified ventricular cardiomyocytes. Cardiovasc. Res. 114:409–416.

Lee, S. H., S. Hadipour-Lakmehsari, T. Miyake, and A. O. Gramolini. 2018. Three-dimensional imaging reveals endo(sarco)plasmic reticulum-containing invaginations within the nucleoplasm of muscle. Am. J. Physiol. Cell. Physiol. 314:C257–C267.

Li, L., G. Chu, E. G. Kranias, and D. M. Bers. 1998. Cardiac myocyte calcium transport in phospholamban knockout mouse: relaxation and endogenous CaMKII effects. Am J Physiol 274:H1335–47.

Li, L., J. Li, B. M. Drum, Y. Chen, H. Yin, X. Guo, et al. 2017a. Loss of AKAP150 promotes pathological remodelling and heart failure propensity by disrupting calcium cycling and contractile reserve. Cardiovasc. Res. 113:147–159.

Li, Z., S. Singh, S. V. Suryavanshi, W. Ding, X. Shen, C. S. Wijaya, et al. 2017b. Force development and intracellular Ca. Eur. J. Pharmacol. 807:117–126.

Ljubojevic, S., and D. M. Bers. 2015. Nuclear calcium in cardiac myocytes. J. Cardiovase. Pharmacol. 65:211–217.
Lygren, B., C. R. Carlson, K. Santamaria, V. Lissandron, T. McSorley, J. Litzenberg, et al. 2007. AKAP complex regulates Ca2+ + re-uptake into heart sarcoplasmic reticulum. EMBO Rep. 8:1061–1067.

Maclellan, D. H., and E. G. Krnias. 2003. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4:566–577.

Maslennikov, I. V., A. G. Sobol, J. Anagli, P. James, T. Vorherr, A. S. Arseniev, et al. 1995. The secondary structure of phospholamban: a two-dimensional NMR study.

Biochem. Biophys. Res. Commun. 217:1200–1207.

Masterson, L. R., C. Cheng, T. Yu, M. Tonelli, A. Kornev, S. S. Masters, J. B., T. M. Klauck, L. K. Langeberg, and J. D. Scott. 2011. 5’ end-centered expression profiling using cap-analysis gene expression and next-generation sequencing.

Nat. Methods 10:131–136.

Mizuho, Y., T. G. Thompson, J. R. Guyon, H. G. Lidow, M. Brosius, M. Imamura, et al. 2001. Desmuslin, an intermediate filament protein that interacts with alpha - dystrobrevin and desmin. Proc. Natl Acad. Sci. USA 98:1656–1661.

Nauert, J. B., T. M. Klauck, L. K. Langeberg, and J. D. Scott. 1997. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr. Biol. 7:52–62.

Pare, G. C., A. L. Bauman, M. McHenry, J. J. Michel, K. L. Dodge-Kafka, and M. S. Kapiloff. 2005a. The mAKAP complex participates in the induction of cardiac myocyte hypertrophy by adrenergic receptor signaling. J. Cell Sci. 118:5637–5646.

Pare, G. C., J. L. Easlick, J. M. Mislow, E. M. McNally, and M. S. Kapiloff. 2005b. Nesprin-1alpha contributes to the targeting of mAKAP to the cardiac myocyte nuclear envelope. Exp. Cell Res. 303:388–399.

Passariello, C. L., J. Li, K. Dodge-Kafka, and M. S. Kapiloff. 2015. mAKAP-a master scaffold for cardiac remodeling. J. Cardiovasc. Pharmacol. 65:218–225.

Rajgor, D., and C. M. Shanahan. 2013. Nesprins: from the nuclear envelope and beyond. Expert Rev. Mol. Med. 15:e5.

Reddy, Y. S. 1976. Phosphorylation of cardiac regulatory proteins by cyclic AMP-dependent protein kinase. Am. J. Physiol. 231:1330–1336.

Rigatti, M., A. V. Le, C. Gerber, I. I. Moraru, and K. L. Dodge-Kafka. 2015. Phosphorylation state-dependent interaction between AKAP76/γ and phospholamban increases phospholamban phosphorylation. Cell. Signal. 27:1807–1815.

Ruehr, M. L., M. A. Russell, and M. Bond. 2004. A-kinase anchoring protein targeting of protein kinase A in the heart. J. Mol. Cell. Cardiol. 37:653–665.

Russell, M. A., L. M. Lund, R. Haber, K. McKeegan, N. Cianciola, and M. Bond. 2006. The intermediate filament protein, synemin, is an AKAP in the heart. Arch. Biochem. Biophys. 456:204–215.

Ryan, T., P. Sharma, A. Ignatchenko, D. H. Maclellan, T. Kislenger, and A. O. Gramolini. 2011. Identification of novel ryanodine receptor 1 (RyR1) protein interaction with calcium homeostasis endoplasmic reticulum protein (CHERP). J. Biol. Chem. 286:17060–17068.

Sankaranarayanan, R., Y. Li, D. J. Greensmith, D. A. Eisner, and L. Venetucci. 2016. Biphasic decay of the Ca transient results from increased sarcoplasmic reticulum Ca leak. J. Physiol. 594:611–623.

Schmitt, J. P., M. Kamisago, M. Asahi, G. H. Li, F. Ahmad, U. Mende, et al. 2003. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299:1410–1413.

Scholten, A., T. A. van Veen, M. A. Vos, and A. J. Heck. 2007. Diversity of cAMP-dependent protein kinase isoforms and their anchoring proteins in mouse ventricular tissue. J. Proteome Res. 6:1705–1717.

Schulze, D. H., M. Muqhal, W. J. Lederer, and A. M. Ruknudin. 2003. Sodium/calcium exchanger (NCX1) macromolecular complex. J. Biol. Chem. 278:28849–28855.

Sharma, P., V. Ignatchenko, K. Grace, C. Ursprung, T. Kislenger, and A. O. Gramolini. 2010. Endoplasmic reticulum protein targeting of phospholamban: a common role for an N-terminal diarginine motif in ER retention? PLoS One 5:e11496.

Simmerman, H. K., and L. R. Jones. 1998. Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol. Rev. 78:921–47.

Smith, F. D., M. H. Omar, P. J. Nygren, J. Soughayer, N. Hoshi, H. T. Lau, et al. 2018. Single nucleotide polymorphisms alter kinase anchoring and the subcellular targeting of A-kinase anchoring proteins. Proc. Natl Acad. Sci. USA 115:E11465–E11474.

Tada, M., and A. M. Katz. 1982. Phosphorylation of the sarcoplasmic reticulum and sarcolemma. Annu. Rev. Physiol. 44:401–423.

Takahashi, H., T. Lassmann, M. Murata, and P. Carninci. 2012. 5’ end-centered expression profiling using cap-analysis gene expression and next-generation sequencing. Nat. Protoc. 7:542–561.

Teng, A. C., T. Miyake, S. Yokoe, L. Zhang, L. M. Rezende, P. Sharma, et al. 2015. Metformin increases degradation of phospholamban via autophagy in cardiomyocytes. Proc. Natl. Acad. Sci. USA 112:7165–7170.

Te Rijdt, W. P., A. Asimaki, J. D. H. Jongbloed, E. T. Hoornije, E. Lazzarini, P. A. van der Zwaag, et al. 2019. Distinct molecular signature of phospholamban p.Arg14del arrhythmogenic cardiomyopathy. Cardiovasc. Pathol. 40:2–6.

Tyanova, S., T. Temu, P. Sinitcyn, A. Carlson, M. Y. Hein, T. Geiger, et al. 2016. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13:731–740.

Uhlén, M., L. Fagerberg, B. M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu, et al. 2015. Proteomics Tissue-based map of the human proteome. Science 347:1260419.
Vassilatis, D. K., J. G. Hohmann, H. Zeng, F. Li, J. E. Ranchalis, M. T. Mortrud, et al. 2003. The G protein-coupled receptor repertoires of human and mouse. Proc. Natl. Acad. Sci. USA 100:4903–4908.

Wu, C. Y., D. H. Dijulio, K. L. Jacobson, G. S. McKnight, and E. L. Watson. 2010. The contribution of AKAP5 in amylase secretion from mouse parotid acini. Am. J. Physiol. Cell Physiol. 298:C1151–C1158.

Wu, A. Z., D. Xu, N. Yang, S. F. Lin, P. S. Chen, S. E. Cala, et al. 2016. Phospholamban is concentrated in the nuclear envelope of cardiomyocytes and involved in perinuclear/nuclear calcium handling. J. Mol. Cell. Cardiol. 100:1–8.

Xiang, Y., and B. K. Kobilka. 2003. Myocyte adrenoceptor signaling pathways. Science 300:1530–1532.

Xiao, R. P., and E. G. Lakatta. 1993. Beta 1-adrenoceptor stimulation and beta 2-adrenoceptor stimulation differ in their effects on contraction, cytosolic Ca2+ current and Ca2+ current in single rat ventricular cells. Circ. Res. 73:286–300.

Yang, J., J. A. Drazba, D. G. Ferguson, and M. Bond. 1998. A-kinase anchoring protein 100 (AKAP100) is localized in multiple subcellular compartments in the adult rat heart. J. Cell Biol. 142:511–522.

Zhao, W., J. R. Waggoner, Z. G. Zhang, C. K. Lam, P. Han, J. Qian, et al. 2009. The antiapoptotic protein HAX-1 is a regulator of cardiac function. Proc. Natl. Acad. Sci. USA 106:20776–20781.

Zhou, T., J. Li, P. Zhao, H. Liu, D. Jia, H. Jia, et al. 2015. Palmitoyl acyltransferase Aph2 in cardiac function and the development of cardiomyopathy. Proc. Natl Acad. Sci. USA 112:15666–15671.

van der Zwaag, P. A., I. A. Van Rijssingen, A. Asimaki, J. D. Jongbloed, D. J. Van Veldhuisen, A. C. Wiesfeld, et al. 2012. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14:1199–1207.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article:

Figure S1. Full blots of protein expression of AKAP6.

Figure S2. Full blots of AKAP6 and PLN immunoprecipitation changes upon mutation and adrenergic stimulation.

Figure S3. Column and scatterplot analysis for AKAP6 and PLN immunoprecipitation changes upon mutation and adrenergic stimulation.

Table S1. List of the main membranous AKAPs found in the human heart.

Table S2. Normalized Mean and SEM of RNA-seq data for AKAPs in human hearts.

Table S3. Normalized Mean and SEM of RNA-seq data of human AKAP candidates in non-hypertrophic and hypertrophic adult human.